US 11,690,814 B2
Suplatast tosilate for use in the treatment of cough associated with interstitial lung disease
John Bondo Hansen, Copenhagen Ø (DK); Mikael S. Thomsen, Hvidovre (DK); and Niels Skjærbæk, Vedbæk (DK)
Assigned to CONRIG PHARMA APS, Copenhagen (DK)
Appl. No. 16/61,572
Filed by Conrig Pharma ApS, Copenhagen N (DK)
PCT Filed Nov. 16, 2016, PCT No. PCT/DK2016/050368
§ 371(c)(1), (2) Date Jun. 12, 2018,
PCT Pub. No. WO2017/108041, PCT Pub. Date Jun. 29, 2017.
Prior Publication US 2019/0254998 A1, Aug. 22, 2019
Int. Cl. A61K 31/167 (2006.01); A61P 11/14 (2006.01); A61K 9/00 (2006.01)
CPC A61K 31/167 (2013.01) [A61K 9/0073 (2013.01); A61P 11/14 (2018.01)] 21 Claims
 
1. A method of alleviating cough in a patient diagnosed with an interstitial lung disease, said method comprising one or more steps of administering a composition comprising a compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salts, esters and crystal forms thereof, to an individual in need thereof, wherein the individual has a cough caused by an interstitial lung disease.